The US Court of Appeals for the Fifth Circuit is reviving PhRMA's legal attack on Medicare drug price negotiations. On Friday ...

This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her ...

The US' Health Resources and Services Administration threatened Johnson & Johnson with fines for unilaterally reshaping the ...

Amer­i­cans can now vac­ci­nate them­selves against the flu with­out the as­sis­tance of a health­care work­er.

Apellis has had its European ambitions dashed once again after regulators reaffirmed their decision to not recommend the ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare ...

An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday.

Novo Nordisk's $1 billion bet last year on a small Canadian biotech could expand the Danish drug giant's arsenal of obesity medicines, but it will first have to address safety concerns. On Friday, Nov ...

Sanofi released new Phase 3 data for its BTK inhibitor tolebrutinib in non-relapsing secondary progressive multiple sclerosis ...

Novo Nordisk has ended one of the multiple trials testing the lead oral drug from its $1.1 billion Forma Therapeutics buyout, ...

Gilead Science’s Kite Pharma is separating from its cell therapy joint venture with Fosun Pharma in China, handing Fosun the ...